WO2010010566A1 - Improved process for the manufacture of ziprasidone - Google Patents
Improved process for the manufacture of ziprasidone Download PDFInfo
- Publication number
- WO2010010566A1 WO2010010566A1 PCT/IN2008/000469 IN2008000469W WO2010010566A1 WO 2010010566 A1 WO2010010566 A1 WO 2010010566A1 IN 2008000469 W IN2008000469 W IN 2008000469W WO 2010010566 A1 WO2010010566 A1 WO 2010010566A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- ziprasidone
- derivative
- iii
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Definitions
- the present invention relates to an improved method for the manufacture of Ziprasidone of the formula (I), chemically known as 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyl)ethyl)- 6-chloro-l,3-dihydro-2H-indol-2-one and identified by the CAS registration number [146939-27-7], which is an antipsychotic agent used for the treatment of schizophrenia.
- Ziprasidone of the formula (I) chemically known as 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyl)ethyl)- 6-chloro-l,3-dihydro-2H-indol-2-one and identified by the CAS registration number [146939-27-7], which is an antipsychotic agent used for the treatment of schizophrenia.
- Ziprasidone of formula (I) is generically covered in the US 4,831,031 that discloses its synthesis by the reaction of 3-piperazinylbenzo[d]isothiazole of formula (II) (hereinafter, PBT) and 6-chloro-5-(2-chloroethyl)indolin-2-one of formula (III) (hereinafter, CEOI) in a polar organic solvent such as ethanol, dimethylformamide or methylisobutyl ketone; in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine or alkali metal base such as sodium carbonate, and in the further presence of catalytic amount of sodium iodide. The final product is purified by chromatography. This method suffers from the following disadvantages,
- US 5,206,366 discloses and claims a process for making Ziprasidone (I) by reacting PBT free base and CEOI in water and in the presence of neutralizing agent sodium carbonate, at refluxing temperature for about 9 to 12 hours.
- the ziprasidone free base is prepared by reacting PBT hydrochloride and CEOI by refluxing hydrochloride salt of (II) with (III) in water and in presence of a neutralizing agent sodium carbonate for about 8 to 16 hours.
- WO 2005/040160 discloses and claims a process of similar coupling in various solvents that include water, alcohols, glycols, sulfolane and tolune, in presence of bases like sodium carbonate.
- WO 2005/085240 discloses and claims similar coupling in water, without employing any base.
- the object of the invention is to provide an improved method to manufacture Ziprasidone (I) without employing external bases and overcoming the short comings of te prior art.
- present invention provides an improved method to manufacture Ziprasidone (I) by the coupling of free base piperazine derivative (II) with oxindole derivative of formula (III) by heating in a non-aqueous suspending liquid, for example, sulfolane, without the need of any external base and optionally in presence of a catalyst.
- a non-aqueous suspending liquid for example, sulfolane
- the coupling reaction of this instant invention is an equimolecular condensation reaction between an amine (piperezine derivative, a nitrogen containing organic base) and a chloroethyl oxindole derivative. During the condensation hydrochloric acid (HCl) is liberated which needs to be scavenged.
- amine piperezine derivative, a nitrogen containing organic base
- chloroethyl oxindole derivative a chloroethyl oxindole derivative
- this instant invention provides a process wherein the piperazine derivative of formula (II) is used in a molar ratio excess to the oxindole derivative of formula (III).
- the preferred molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1:1 and 2.5:1, more preferably between 1.2:1 and 2:1.
- the excess quantity of the piperizine derivative (II) captures the HCl. Hence the reaction takes place even without the addition of any external inorganic or organic base.
- the said coupling of the free base piperazine derivative (II) with oxindole derivative of formula (III) is effected by heating the mixture of (II) and (III) in a non-aqueous suspending liquid, for example, sulfolane, at a temperature in the range of 50° to 15O 0 C. The most preferred temperature is 80-90 0 C.
- Alkali metal halides for example, sodium or potassium iodides, are optionally used in the reaction as a catalyst.
- the process of the present invention results in a pure ziprasidone, which precipitates as a filterable solid mass.
- the product may be purified by washing with acetone.
- the ziprasidone obtained by the process of the present invention can be converted to its hydrochloride or other pharmaceutically acceptable salts by known methods.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
An improved method for preparing a compound of formula (I): which comprises of coupling the piperazine derivative of formula (II) with oxindole derivative of formula (III): by heating in a non-aqueous medium, in the absence of an external base and optionally in presence of a catalyst.
Description
IMPROVED PROCESS FOR THE MANUFACTURE OF ZIPRASIDONE
FIELD OF INVENTION
The present invention relates to an improved method for the manufacture of Ziprasidone of the formula (I), chemically known as 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyl)ethyl)- 6-chloro-l,3-dihydro-2H-indol-2-one and identified by the CAS registration number [146939-27-7], which is an antipsychotic agent used for the treatment of schizophrenia.
BACKGROUND OF THE INVENTION
Ziprasidone of formula (I) is generically covered in the US 4,831,031 that discloses its synthesis by the reaction of 3-piperazinylbenzo[d]isothiazole of formula (II) (hereinafter, PBT) and 6-chloro-5-(2-chloroethyl)indolin-2-one of formula (III) (hereinafter, CEOI) in a polar organic solvent such as ethanol, dimethylformamide or methylisobutyl ketone; in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine or alkali metal base such as sodium carbonate, and in the further presence of catalytic amount of sodium iodide. The final product is purified by chromatography. This method suffers from the following disadvantages,
1) Longer reaction time of 24 to 72 hours,
2) Formation of considerable quantities of by products,
3) Special purification techniques like chromatography and,
Moreover, when practiced in the laboratory, the process of US 4,831,031 resulted in low yield from 14 to 22%.
US 5,206,366 discloses and claims a process for making Ziprasidone (I) by reacting PBT free base and CEOI in water and in the presence of neutralizing agent sodium carbonate, at refluxing temperature for about 9 to 12 hours.
US 5,338,846, which is a continuation-in-part of US 5,206,366, discloses and claims a process for the preparation of hydrochloride salt of Ziprasidone (I). The ziprasidone free base is prepared by reacting PBT hydrochloride and CEOI by refluxing hydrochloride salt of (II)
with (III) in water and in presence of a neutralizing agent sodium carbonate for about 8 to 16 hours.
WO 2005/040160 discloses and claims a process of similar coupling in various solvents that include water, alcohols, glycols, sulfolane and tolune, in presence of bases like sodium carbonate.
WO 2005/085240 discloses and claims similar coupling in water, without employing any base.
The above-mentioned methods have the following disadvantages,
1) Require tedious purification procedures such as chromatographic separation.
2) The presence of base, as per the prior art disclosed methods discussed hereinbefore, increases impurity level of the reaction mass so that it becomes a dark, thick gummy mass which does not allow precipitation of the product as a filterable solid mass. The residue needs further tedious purification that increases the cost of the process and decreases process efficiency.
Surprisingly, the present inventors have found that the above coupling reaction to manufacture Ziprasidone (I) can be effectively carried out by mixing 3- piperazinylbenzo[d]isothiazole (II) and 6-chloro-5-(2-chloroethyl)indolin-2-one (III) and heating in the presence of catalytic amount of alkali metal halide such as potassium iodide in a non-aqueous medium, for instance sulfolane, without employing such external bases, thus overcoming the limitations of the prior art discussed hereinbefore.
OBJECTS OF THE INVENTION
Thus the object of the invention is to provide an improved method to manufacture Ziprasidone (I) without employing external bases and overcoming the short comings of te prior art.
SUMMARY OF THE INVENTION
Thus present invention provides an improved method to manufacture Ziprasidone (I) by the coupling of free base piperazine derivative (II) with oxindole derivative of formula (III) by heating in a non-aqueous suspending liquid, for example, sulfolane, without the need of any external base and optionally in presence of a catalyst.
(H) (in) (I)
DETAILED DESCRIPTION OF THE INVENTION The coupling reaction of this instant invention is an equimolecular condensation reaction between an amine (piperezine derivative, a nitrogen containing organic base) and a chloroethyl oxindole derivative. During the condensation hydrochloric acid (HCl) is liberated which needs to be scavenged.
Accordingly, this instant invention provides a process wherein the piperazine derivative of formula (II) is used in a molar ratio excess to the oxindole derivative of formula (III). The preferred molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1:1 and 2.5:1, more preferably between 1.2:1 and 2:1. The excess quantity of the piperizine derivative (II) captures the HCl. Hence the reaction takes place even without the addition of any external inorganic or organic base.
The said coupling of the free base piperazine derivative (II) with oxindole derivative of formula (III) is effected by heating the mixture of (II) and (III) in a non-aqueous suspending
liquid, for example, sulfolane, at a temperature in the range of 50° to 15O0C. The most preferred temperature is 80-900C.
Alkali metal halides, for example, sodium or potassium iodides, are optionally used in the reaction as a catalyst.
The process of the present invention results in a pure ziprasidone, which precipitates as a filterable solid mass. The product may be purified by washing with acetone.
The ziprasidone obtained by the process of the present invention can be converted to its hydrochloride or other pharmaceutically acceptable salts by known methods.
The invention is further illustrated by the following non-limiting example.
Example 1
Preparation of 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyI)ethyI)-6-chIoro-l,3- dihydro-2H-indol-2-one (Ziprasidone)
To a solution of sulfolane (69 ml), 5-(2-chloroethyl)-6-chloro-oxindole (23 g, 0.1 mole) and l-(l,2-benzothiozol-3-yl) piperazine (43.7 g, 0.2 mole), KI (1.15 g, 5%) was added at 30- 350C. The mixture was slowly heated under stirring to 80-900C over 60-90min. The mixture was stirred for 24-26 hr, after completion of the reaction as monitored by HPLC, the reaction mass was cooled to room temperature. Added water (230 ml) and stirred the reaction mass for 60 min. The solid was filtered and washed with water (115 ml). Suck dry the solid for 2 hr. The wet solid was stirred with acetone (230 ml) for 60 min. Filtered the solid with acetone (50 ml) dried the solid under vacuum at 4O0C for 4-5 hr. Yield: 24 g (57%) Purity by HPLC: - 90%
Claims
1. A process for preparing the compound of formula (I)
comprising of reacting a piperazine derivative of formula (II) and an oxindole derivative of formula (III),
(H) (III)
in a non-aqueous suspending liquid, in the absence of an external base, optionally in presence of a catalyst.
2. The process as claimed in claim 1, wherein the molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1:1 and 2.5:1.
3. The process as claimed in claim 1, wherein the molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1.2:1 and 2:1.
4. The process as claimed in any of the preceding claims wherein the non-aqueous suspending liquid is sulfolane.
5. The process as claimed in any of the preceding claims wherein the catalyst is selected from sodium iodide and potassium iodide.
6. The process as claimed in any of the preceding claims wherein the temperature of the reaction is in the range of 50° to 15O0C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2008/000469 WO2010010566A1 (en) | 2008-07-25 | 2008-07-25 | Improved process for the manufacture of ziprasidone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2008/000469 WO2010010566A1 (en) | 2008-07-25 | 2008-07-25 | Improved process for the manufacture of ziprasidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010010566A1 true WO2010010566A1 (en) | 2010-01-28 |
Family
ID=40262306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2008/000469 Ceased WO2010010566A1 (en) | 2008-07-25 | 2008-07-25 | Improved process for the manufacture of ziprasidone |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010010566A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040160A2 (en) * | 2003-10-24 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| WO2005085240A2 (en) * | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Process for the preparation of ziprasidone |
| WO2006011157A2 (en) * | 2004-06-18 | 2006-02-02 | Lupin Limited | Methods for the preparation of aryl piperazinyl-heterocyclic compounds |
-
2008
- 2008-07-25 WO PCT/IN2008/000469 patent/WO2010010566A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040160A2 (en) * | 2003-10-24 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| WO2005085240A2 (en) * | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Process for the preparation of ziprasidone |
| WO2006011157A2 (en) * | 2004-06-18 | 2006-02-02 | Lupin Limited | Methods for the preparation of aryl piperazinyl-heterocyclic compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8993778B2 (en) | Process for manufacture of telmisartan | |
| WO2012068441A2 (en) | Intedanib salts and solid state forms thereof | |
| JP5016575B2 (en) | A novel synthesis of strontium ranelate and its hydrates | |
| US20140221652A1 (en) | Improved process for preparation of imatinib and its mesylate salt | |
| US20050143396A1 (en) | Novel crystalline forms of ziprasidone hydrochloride | |
| KR20140128926A (en) | Process for the production of bendamustine alkyl ester, bendamustine, and derivatives thereof | |
| CN101939314A (en) | Polymorphs of 3-pyrrole-substituted 2-indolinones | |
| CZ296543B6 (en) | 1,2,4-Trisubstituted imidazole compound and quaternary salt of 1,2,3,4-tetrasubstituted imidazole compound | |
| CN111757870A (en) | Method for synthesizing sulfentrazone | |
| WO2010010566A1 (en) | Improved process for the manufacture of ziprasidone | |
| EP1026163B1 (en) | Process for producing substituted alkylamines or salts thereof | |
| CN101171251A (en) | The preparation method of aztreonam | |
| US7601832B2 (en) | Process for making aztreonam | |
| CN101245078B (en) | Benzathine salt of ceftiofur, preparation method and application thereof | |
| EP1845088B1 (en) | An improved process for the preparation of aripipirazole | |
| KR102702677B1 (en) | Process for Preparation of Fimasartan and Intermediate for Preparing the Same | |
| JP6210599B2 (en) | Process for producing 4-methyl-6 (1-methylbenzimidazol-2-yl) -2-n-propyl-1H-benzimidazole | |
| US7087611B2 (en) | Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride) | |
| US8129536B2 (en) | Method for the purification of lansoprazole | |
| US7728136B2 (en) | Method for the preparation of aryl piperazinyl-heterocyclic compounds | |
| US20080214816A1 (en) | Process for Preparing Ziprasidone | |
| KR100351743B1 (en) | Process for preparation of the n,n-dicyclohexyl-2-benzothiazole sulfenamide | |
| US20080312254A1 (en) | Process for the Preparation of Ziprasidone | |
| WO2011080749A1 (en) | Process for purification of ziprasidone | |
| US20070078143A1 (en) | Method for preparing Ziprasidone monohydrochloride-hydrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08789920 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08789920 Country of ref document: EP Kind code of ref document: A1 |